Ongoing projects
- NOR-MS: a national multicenter non-inferiority study of two highly efficient MS therapies (cladibine and rituximab)
- NevroVAX: a national study of immune responses to vaccines in persons with MS
- OVERLORD MS: local PI and responsible for the primaty endpoint of the national multicenter non-inferiority study of two highly efficient MS therapies (ocrelizumab and rituximab), lead from Haukeland University Hospital
- HMAS for MS ved OUS: a prospective study of persons with MS treated with stem cell therapy at OUH.